CBIS cannabis extract treats autism?
DENDRONISTA
Partner to Advance Successful Cannabis-based Autism Treatments
Last Update: 3/17/2011 8:57:03 AM
Cannabis Science and The Unconventional Foundation for Autism (UF4A)
Partner to Advance Successful Cannabis-based Autism Treatments
Results Documented By Health Care Professionals At The University of
California Irvine Medical Center (UCI), Dr. Melamede to join UF4A
Board
COLORADO SPRINGS, Colo., Mar 17, 2011 (BUSINESS WIRE) -- Cannabis
Science, Inc. (CBIS), a pioneering US biotech company developing
pharmaceutical cannabis products, is pleased to announce the
partnership with The Unconventional Foundation for Autism (UF4A) to
build on the Foundation's success with its proprietary cannabinoid
formulations for Autism treatment. The partnership will focus on
advancing the medical cannabis treatments for Autism in conjunction
with the successful cannabis treatments of Joey and 10 other families
that are now being documented by The University of California Irvine
Medical Center (UCI) for the Foundation.
These successful Autism treatments and pioneering efforts of Joey's
Mom, Mieko Hester Perez, can be fully reviewed at .
Mieko and the successful treatment of her son has garnered wide-
spread
media interest including television appearances and interviews with
KABC 7 - Los Angeles & San Francisco, 20/20 ABC, Good Morning
America,
Fox Morning News, Fox News Rhode Island, CBS Early Show, KCAL 9 & CBS
2 Los Angeles, The Doctor's TV Show, KABC 790 w/ Peter Tilden, Montel
Williams, The Tom Joyner Show, The Kim Frasier Show w/ Dr. Lester
Grinspoon, The Bill Press Show, NORML's Podcast w/ Russ Belville,
Thomasina Tafur radio show. Featured interviews: Autism Spectrum
Magazine, Treating yourself Magazine, Huffington Post, Autism Spot,
Celebstoner, disability scoop, Autism Support Network, Kush Magazine
August 2010 Issue Cover, High Times Medical Marijuana Magazine Winter
2011 Issue, Treating yourself Magazine (Joey's sibling interviewed
Issue #23, Weed World UK Issue #89, Now Magazine UK Publications,
Medical Cannabis Journal Issue, LA JEMM - Ethical Use of Medical
Marijuana in the Treatment of Children with Autism, Orange County
Register, California, The Revolution - Argentina publication. 2010
Recognized by the National Organization to Reform Marijauna Laws
Woman's Alliance as one of the woman making history in the medical
marijuana movement.
Mieko Hester Perez, Founder and Executive Director of The
Unconventional Foundation for Autism (UF4A) stated, "We believe that
this new partnership with Cannabis Science will give us additional
push and resources required to advance our Autism research. To date,
we have already partnered with the University of California Irvine
Medical Center to oversee our cannabis-based Autism research.
Included
in this group of advisors is the Dean of Medicine at UCI, and child
psychiatrist Dr. Rebecca Hedrick M.D. Dr. Melamede of Cannabis
Science
will be an outstanding addition to the Board of the Foundation. His
extensive knowledge of cannabinoid science should prove invaluable in
our mission."
As part of the new partnership, Dr. Robert Melamede, CEO of Cannabis
Science, will be joining the board of UF4A as a scientific advisor.
Dr. Melamede will work with UF4A to further assist in documenting the
case studies and oversee the deployment of the Company's proprietary
cannabinoid treatments on Autism patients alongside UF4A and medical
professionals. He will also work with UF4A's legal advisors to
progress the legalization of medical marijuana initiatives.
Dr. Robert Melamede Ph.D., Cannabis Science Inc., President & CEO,
stated, "Cannabis Science's partnership with UF4A is another
instrumental step in reaching our long-term goal of FDA approval of
the Company's products. The successful results from the Autism
patients treated as documented by UF4A are very encouraging and we're
excited to tap into UF4A's proven track record; providing our
scientific expertise to help develop more refined treatment plans
with
Cannabis Science's formulations and extracts to achieve
scientifically
accepted patient outcomes. I'm also extremely excited to be working
with the medical professionals at the University of California
Irvine.
This is a win-win for both our organizations in breaking new ground
for medical cannabis treatments. Our partnership will enable both our
Company and UF4A to expound upon studies and anecdotal evidence
obtained by UF4A in order to catalogue verified case studies and
solid
science behind the treatment plans. This evidentiary step will help
the UF4A and Cannabis Science partnership to move towards formal FDA
testing to officially approve UF4A's successful treatments of Autism
using medical cannabinoid extracts and formulations under the
direction of physicians. "
UF4A Case Studies
Mieko Hester-Perez and her son "Joey" have inspired many additional
parents with autistic children to step forward. Studies are underway
with these children with oversight from Child & Adolescent
Psychiatrist Dr. Rebecca M. Hedrick, M.D.
Dr. Hedrick is a child and adolescent emergency attending physician
and covers the consult liaison service at UCI Medical. She runs a
child and adolescent outpatient psychotherapy and medication
management program. She also works with the Regional Center of Orange
County in the treatment of individuals with developmental
disabilities.
Associate Training Director, Psychiatry & Human Behavior School of
Medicine M.D., Phone: (714) 456-8775 Fax: (714) 456-7605 Email:
rhedr...@uci.edu
About UF4A
The Unconventional Foundation for Autism, UF4A for short, is a non-
profit organization. The mission of UF4A is three fold: (1) to raise
awareness and support for families afflicted with this mysterious and
misunderstood condition known as Autism; (2) to raise funds for
cannabis-based medical research and clinical trials; and (3) to
campaign for a rescheduling of cannabis from Schedule 1 narcotic (no
accepted medical benefits) to a lower schedule so that the
appropriate
research may be conducted, and so that all patients have access to
medication. A listing on Schedule 1 is tantamount to a research
blockade and, frankly, is unacceptable where millions continue to
needlessly suffer and subject to criminal punishment should they
choose to use cannabis under the direction of their physician. The
Schedule 1 listing fails to reflect the prevailing medical view that
cannabis has accepted medical benefits. UF4A is quickly becoming a
leading advocate in the fight for nationwide investigation, research
and analysis of the legalization of Medical Marijuana.
The partnership promises to advance the innovative medical autism
research headed by Executive Director Mieko Hester- Perez. The
Unconventional Foundation Autism's partnership focus is to bridge the
gap between parents, scientists, and medical professionals to provide
a better quality of life for our children diagnosed with the
misunderstood condition known as Autism.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade
medical marijuana research and development. The Company works with
world authorities on phytocannabinoid science targeting critical
illnesses, and adheres to scientific methodologies to develop,
produce
and commercialize phytocannabinoid-based pharmaceutical products. In
sum, we are dedicated to the creation of cannabis-based medicines,
both with and without psychoactive properties, to treat disease and
the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
Forward Looking Statements; This Press Release includes forward-
looking statements within the meaning of Section 27A of the
Securities
Act of 1933 and Section 21E of the Securities Act of 1934. A
statement
containing works such as "anticipate," "seek," intend," "believe,"
"plan," "estimate," "expect," "project," "plan," or similar phrases
may be deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of the
events or results anticipated by these forward-looking statements may
not occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc. does not undertake any duty nor does it intend to
update
the results of these forward-looking statements.
SOURCE: Cannabis Science, Inc.
Copyright Business Wire 2011